ConCallIQ
Go Pro
Home › Aarti Drugs › Revenue History

Aarti Drugs Revenue History — Quarter by Quarter

Aarti Drugs's revenue moved from ₹653 Cr in Q2 FY26 to ₹721 Cr in Q4 FY26, a 10.4% change over 3 quarters. The table keeps each quarter linked back to the underlying earnings page.

Revenue by Quarter

QuarterRevenue (₹ Cr)YoY Change
Q4 FY26₹721 Cr+6%
Q3 FY26₹603 Cr+8.2%
Q2 FY26₹653 Cr+9%

What management said about revenue

G

Q4 FY26 · Methylamine plant utilization target 55-60% in Q1 FY27

Management expects to cross 55-60% utilization in the June quarter, with a path to >70% within a year.

G

Q4 FY26 · Volume growth target of 8-10% for FY27

Management targets 8-10% volume growth, with internal aspirations of 10-15%, supported by new capacities.

G

Q3 FY26 · Volume growth of 12-15% in FY27

Management expects 12-15% volume growth in FY27, driven by new products (salicylic acid, methylamines) and single-digit growth in existing basket.

G

Q3 FY26 · Sikar plant utilization to reach 50% by March 2026, 75% next quarter

Sikar facility expected to ramp to 50% utilization in Q4 FY26 and 75% in the subsequent quarter, with full utilization within 12 months.

G

Q2 FY26 · High single-digit value growth in H2 FY26

Management aims for high single-digit value growth in H2 FY26, driven by export demand and new capacities.

G

Q2 FY26 · 15-20% revenue growth aspiration for FY27

If salicylic acid ramp-up succeeds, management expects 15-20% revenue growth in FY27.